Published in Mar Drugs on March 21, 2011
Astaxanthin: sources, extraction, stability, biological activities and its commercial applications--a review. Mar Drugs (2014) 1.56
Astaxanthin protects ARPE-19 cells from oxidative stress via upregulation of Nrf2-regulated phase II enzymes through activation of PI3K/Akt. Mol Vis (2013) 1.04
Enhancement of carotenoid production by disrupting the C22-sterol desaturase gene (CYP61) in Xanthophyllomyces dendrorhous. BMC Microbiol (2012) 0.97
ROS-mediated platelet generation: a microenvironment-dependent manner for megakaryocyte proliferation, differentiation, and maturation. Cell Death Dis (2013) 0.85
Astaxanthin-Producing Green Microalga Haematococcus pluvialis: From Single Cell to High Value Commercial Products. Front Plant Sci (2016) 0.85
Nutraceuticals for geriatrics. J Tradit Complement Med (2014) 0.85
Heavy Metals and Human Health: Mechanistic Insight into Toxicity and Counter Defense System of Antioxidants. Int J Mol Sci (2015) 0.84
Carotenoids: potential allies of cardiovascular health? Food Nutr Res (2015) 0.84
Elucidation of the pathway to astaxanthin in the flowers of Adonis aestivalis. Plant Cell (2011) 0.84
Astaxanthin from Haematococcus pluvialis Prevents Oxidative Stress on Human Endothelial Cells without Toxicity. Mar Drugs (2015) 0.83
Astaxanthin as a Potential Neuroprotective Agent for Neurological Diseases. Mar Drugs (2015) 0.82
Carotenoids from Marine Microalgae: A Valuable Natural Source for the Prevention of Chronic Diseases. Mar Drugs (2015) 0.81
Response surface methodology for ultrasound-assisted extraction of astaxanthin from Haematococcus pluvialis. Mar Drugs (2013) 0.80
A combination of flaxseed oil and astaxanthin alleviates atherosclerosis risk factors in high fat diet fed rats. Lipids Health Dis (2014) 0.79
Carotenoids and total phenolic contents in plant foods commonly consumed in Korea. Nutr Res Pract (2012) 0.77
Free Radical Scavenging and Cellular Antioxidant Properties of Astaxanthin. Int J Mol Sci (2016) 0.77
Evaluation of hepatoprotective and antioxidant activity of astaxanthin and astaxanthin esters from microalga-Haematococcus pluvialis. J Food Sci Technol (2015) 0.77
Protective effects of astaxanthin against ischemia/reperfusion induced renal injury in mice. J Transl Med (2015) 0.77
Astaxanthin and Docosahexaenoic Acid Reverse the Toxicity of the Maxi-K (BK) Channel Antagonist Mycotoxin Penitrem A. Mar Drugs (2016) 0.75
Marine carotenoids and oxidative stress. Mar Drugs (2012) 0.75
Astaxanthin affects oxidative stress and hyposalivation in aging mice. J Clin Biochem Nutr (2016) 0.75
A Combination of Flaxseed Oil and Astaxanthin Improves Hepatic Lipid Accumulation and Reduces Oxidative Stress in High Fat-Diet Fed Rats. Nutrients (2017) 0.75
Astaxanthin attenuates total body irradiation-induced hematopoietic system injury in mice via inhibition of oxidative stress and apoptosis. Stem Cell Res Ther (2017) 0.75
Biocompatible astaxanthin as a novel marine-oriented agent for dual chemo-photothermal therapy. PLoS One (2017) 0.75
Rapid Estimation of Astaxanthin and the Carotenoid-to-Chlorophyll Ratio in the Green Microalga Chromochloris zofingiensis Using Flow Cytometry. Mar Drugs (2017) 0.75
Lobster processing by-products as valuable bioresource of marine functional ingredients, nutraceuticals, and pharmaceuticals. Bioresour Bioprocess (2017) 0.75
Scavenging of reactive oxygen species by astaxanthin inhibits epithelial-mesenchymal transition in high glucose-stimulated mesothelial cells. PLoS One (2017) 0.75
Evaluation of Antioxidant, Hypolipidemic, and Antiatherogenic Property of Lycopene and Astaxanthin in Atherosclerosis-induced Rats. Pharmacognosy Res (2017) 0.75
The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med (1994) 16.96
Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med (1996) 10.09
Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med (1996) 8.57
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med (2001) 7.69
MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 7.41
Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS) Lancet (1996) 6.48
Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med (1993) 6.37
Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet (2000) 6.19
Vitamin E consumption and the risk of coronary disease in women. N Engl J Med (1993) 5.39
Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med (2000) 5.09
Beta-carotene supplementation and incidence of cancer and cardiovascular disease: the Women's Health Study. J Natl Cancer Inst (1999) 4.27
beta-Carotene: an unusual type of lipid antioxidant. Science (1984) 2.76
Haematococcus astaxanthin: applications for human health and nutrition. Trends Biotechnol (2003) 2.56
Antioxidant functions of carotenoids. Free Radic Biol Med (1989) 2.11
Carotenoid biosynthesis in microorganisms and plants. Eur J Biochem (1994) 1.93
Antioxidant vitamin intake and coronary mortality in a longitudinal population study. Am J Epidemiol (1994) 1.82
Serum carotenoids and coronary heart disease. The Lipid Research Clinics Coronary Primary Prevention Trial and Follow-up Study. JAMA (1994) 1.70
Why have antioxidants failed in clinical trials? Am J Cardiol (2008) 1.69
A prospective study of consumption of carotenoids in fruits and vegetables and decreased cardiovascular mortality in the elderly. Ann Epidemiol (1995) 1.66
Astaxanthin, a carotenoid with potential in human health and nutrition. J Nat Prod (2006) 1.52
The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation (2003) 1.41
Astaxanthin inhibits nitric oxide production and inflammatory gene expression by suppressing I(kappa)B kinase-dependent NF-kappaB activation. Mol Cells (2003) 1.40
Natural products as a robust source of new drugs and drug leads: past successes and present day issues. Am J Cardiol (2008) 1.36
Astaxanthin: a novel potential treatment for oxidative stress and inflammation in cardiovascular disease. Am J Cardiol (2008) 1.36
Effects of astaxanthin on lipopolysaccharide-induced inflammation in vitro and in vivo. Invest Ophthalmol Vis Sci (2003) 1.32
Antioxidants in cardiovascular health and disease: key lessons from epidemiologic studies. Am J Cardiol (2008) 1.27
Inhibition of low-density lipoprotein oxidation by astaxanthin. J Atheroscler Thromb (2000) 1.21
Prevention of diabetic nephropathy by treatment with astaxanthin in diabetic db/db mice. Biofactors (2004) 1.16
Antioxidants in the prevention of human atherosclerosis. Summary of the proceedings of a National Heart, Lung, and Blood Institute Workshop: September 5-6, 1991, Bethesda, Maryland. Circulation (1992) 1.15
Antihypertensive and neuroprotective effects of astaxanthin in experimental animals. Biol Pharm Bull (2005) 1.14
Astaxanthin limits exercise-induced skeletal and cardiac muscle damage in mice. Antioxid Redox Signal (2003) 1.14
Carotenoids and antioxidants in age-related maculopathy italian study: multifocal electroretinogram modifications after 1 year. Ophthalmology (2007) 1.10
Plasma vitamins E and A inversely correlated to mortality from ischemic heart disease in cross-cultural epidemiology. Ann N Y Acad Sci (1989) 1.10
Safety of an astaxanthin-rich Haematococcus pluvialis algal extract: a randomized clinical trial. J Med Food (2003) 1.10
Low dietary intake of beta-carotene, alpha-tocopherol and ascorbic acid is associated with increased inflammatory and oxidative stress status in a Swedish cohort. Br J Nutr (2008) 1.07
Astaxanthin, a dietary carotenoid, protects retinal cells against oxidative stress in-vitro and in mice in-vivo. J Pharm Pharmacol (2008) 1.04
Dietary antioxidants and risk of myocardial infarction in the elderly: the Rotterdam Study. Am J Clin Nutr (1999) 1.04
Differential effects of carotenoids on lipid peroxidation due to membrane interactions: X-ray diffraction analysis. Biochim Biophys Acta (2006) 1.02
The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part II: Clinical trial evidence (acute coronary syndromes through renal disease) and future directions. Circulation (2006) 1.02
The effects of vitamin C supplementation on protein oxidation in healthy volunteers. Biochem Biophys Res Commun (2000) 1.02
Astaxanthin inhibits reactive oxygen species-mediated cellular toxicity in dopaminergic SH-SY5Y cells via mitochondria-targeted protective mechanism. Brain Res (2008) 1.01
Astaxanthin protects mesangial cells from hyperglycemia-induced oxidative signaling. J Cell Biochem (2008) 1.00
Dietary carotenoids and risk of coronary artery disease in women. Am J Clin Nutr (2003) 1.00
Astaxanthin protects beta-cells against glucose toxicity in diabetic db/db mice. Redox Rep (2002) 0.99
Biologic activity of carotenoids related to distinct membrane physicochemical interactions. Am J Cardiol (2008) 0.99
Astaxanthin improves muscle lipid metabolism in exercise via inhibitory effect of oxidative CPT I modification. Biochem Biophys Res Commun (2007) 0.99
Plasma appearance of unesterified astaxanthin geometrical E/Z and optical R/S isomers in men given single doses of a mixture of optical 3 and 3'R/S isomers of astaxanthin fatty acyl diesters. Comp Biochem Physiol C Toxicol Pharmacol (2004) 0.95
Effects of astaxanthin supplementation on lipid peroxidation. Int J Vitam Nutr Res (2007) 0.94
Effect of astaxanthin on the hepatotoxicity, lipid peroxidation and antioxidative enzymes in the liver of CCl4-treated rats. Methods Find Exp Clin Pharmacol (2001) 0.93
The chemistry of novel xanthophyll carotenoids. Am J Cardiol (2008) 0.93
Antihypertensive potential and mechanism of action of astaxanthin: III. Antioxidant and histopathological effects in spontaneously hypertensive rats. Biol Pharm Bull (2006) 0.91
Astaxanthin, a carotenoid without vitamin A activity, augments antibody responses in cultures including T-helper cell clones and suboptimal doses of antigen. J Nutr (1995) 0.90
Astaxanthin, canthaxanthin and beta-carotene differently affect UVA-induced oxidative damage and expression of oxidative stress-responsive enzymes. Exp Dermatol (2008) 0.90
Effects of astaxanthin on the production of NO and the expression of COX-2 and iNOS in LPS-stimulated BV2 microglial cells. J Microbiol Biotechnol (2008) 0.87
Seven day oral supplementation with Cardax (disodium disuccinate astaxanthin) provides significant cardioprotection and reduces oxidative stress in rats. Mol Cell Biochem (2006) 0.87
Disodium Disuccinate Astaxanthin (Cardax) attenuates complement activation and reduces myocardial injury following ischemia/reperfusion. J Pharmacol Exp Ther (2005) 0.87
Oral bioavailability of the antioxidant astaxanthin in humans is enhanced by incorporation of lipid based formulations. Eur J Pharm Sci (2003) 0.87
Effect of astaxanthin in combination with alpha-tocopherol or ascorbic acid against oxidative damage in diabetic ODS rats. J Nutr Sci Vitaminol (Tokyo) (2008) 0.86
Cardioprotection and myocardial salvage by a disodium disuccinate astaxanthin derivative (Cardax). Life Sci (2004) 0.86
Astaxanthin vs placebo on arterial stiffness, oxidative stress and inflammation in renal transplant patients (Xanthin): a randomised controlled trial. BMC Nephrol (2008) 0.85
Ulcer preventive and antioxidative properties of astaxanthin from Haematococcus pluvialis. Eur J Pharmacol (2008) 0.85
Vitamin C consumption is associated with less progression in carotid intima media thickness in elderly men: A 3-year intervention study. Nutr Metab Cardiovasc Dis (2008) 0.84
Disodium disuccinate astaxanthin prevents carotid artery rethrombosis and ex vivo platelet activation. Pharmacology (2008) 0.84
Gastric inflammatory markers and interleukins in patients with functional dyspepsia treated with astaxanthin. FEMS Immunol Med Microbiol (2007) 0.84
Cardiovascular disease and nutrient antioxidants: role of low-density lipoprotein oxidation. Crit Rev Food Sci Nutr (1995) 0.83
Serum vitamins, carotenoids, and angina pectoris: findings from the National Health and Nutrition Examination Survey III. Ann Epidemiol (2000) 0.83
Novel astaxanthin prodrug (CDX-085) attenuates thrombosis in a mouse model. Thromb Res (2010) 0.83
beta-Carotene interferes with ultraviolet light A-induced gene expression by multiple pathways. J Invest Dermatol (2005) 0.81
Modulation of transcriptional activity by antioxidant carotenoids. Mol Aspects Med (2003) 0.81
Association between atherosclerosis and newly classified chronic kidney disease stage for Japanese patients with type 2 diabetes. Diabetes Res Clin Pract (2009) 0.81
Disodium disuccinate astaxanthin (Cardax): antioxidant and antiinflammatory cardioprotection. Cardiovasc Drug Rev (2005) 0.81
Effect of astaxanthin supplementation on inflammation and cardiac function in BALB/c mice. Anticancer Res (2010) 0.81
Bioavailability of astaxanthin stereoisomers from wild (Oncorhynchus spp.) and aquacultured (Salmo salar) salmon in healthy men: a randomised, double-blind study. Br J Nutr (2007) 0.80
Acute and chronic administration of disodium disuccinate astaxanthin (Cardax) produces marked cardioprotection in dog hearts. Mol Cell Biochem (2005) 0.79
Oxidative remodeling of plastid carotenoids. Arch Biochem Biophys (2004) 0.79
Oral alpha-tocopherol supplementation inhibits lipid oxidation in established human atherosclerotic lesions. Free Radic Res (2003) 0.77
The in vitro effects of Xancor, a synthetic astaxanthine derivative, on hemostatic biomarkers in aspirin-naïve and aspirin-treated subjects with multiple risk factors for vascular disease. Am J Ther (2010) 0.77
Omega-3 polyunsaturated fatty acids in the treatment of kidney disease. Am J Kidney Dis (2010) 2.32
Biomarkers in chronic kidney disease: a review. Kidney Int (2011) 2.25
Oxidative stress biomarkers as predictors of cardiovascular disease. Int J Cardiol (2011) 2.11
Mechanical ventilation results in progressive contractile dysfunction in the diaphragm. J Appl Physiol (1985) (2002) 1.89
Oxidative stress in half and full Ironman triathletes. Med Sci Sports Exerc (2007) 1.68
Association of cardiac autonomic neuropathy with subclinical myocardial dysfunction in type 2 diabetes. JACC Cardiovasc Imaging (2010) 1.62
Oxidative stress, anti-oxidant therapies and chronic kidney disease. Nephrology (Carlton) (2012) 1.61
QT interval variability in type 2 diabetic patients with cardiac sympathetic dysinnervation assessed by 123I-metaiodobenzylguanidine scintigraphy. J Cardiovasc Electrophysiol (2012) 1.41
Effects of antioxidant supplementation on blood cyclosporin A and glomerular filtration rate in renal transplant recipients. Nephrol Dial Transplant (2005) 1.41
Validation of a generalized transfer function to noninvasively derive central blood pressure during exercise. Hypertension (2006) 1.40
Plasma cytokine changes in relation to exercise intensity and muscle damage. Eur J Appl Physiol (2005) 1.33
Exercise-induced muscle damage, plasma cytokines, and markers of neutrophil activation. Med Sci Sports Exerc (2005) 1.29
Metabolic syndrome in severe chronic kidney disease: Prevalence, predictors, prognostic significance and effects of risk factor modification. Nephrology (Carlton) (2007) 1.28
Antioxidant supplementation reduces skeletal muscle mitochondrial biogenesis. Med Sci Sports Exerc (2011) 1.23
Relationships between single nucleotide polymorphisms of antioxidant enzymes and disease. Gene (2012) 1.19
Improved resistance to serum oxidation in Gilbert's syndrome: a mechanism for cardiovascular protection. Atherosclerosis (2007) 1.16
Antioxidant supplementation during exercise training: beneficial or detrimental? Sports Med (2011) 1.14
Interval training program optimization in highly trained endurance cyclists. Med Sci Sports Exerc (2002) 1.08
Exercise capacity and muscle strength in patients with cirrhosis. Liver Transpl (2012) 1.07
The influence of antioxidant supplementation on markers of inflammation and the relationship to oxidative stress after exercise. J Nutr Biochem (2006) 1.07
Reduced circulating oxidized LDL is associated with hypocholesterolemia and enhanced thiol status in Gilbert syndrome. Free Radic Biol Med (2012) 1.06
Astaxanthin, oxidative stress, inflammation and cardiovascular disease. Future Cardiol (2009) 1.04
Exercise prescription for patients with type 2 diabetes and pre-diabetes: a position statement from Exercise and Sport Science Australia. J Sci Med Sport (2011) 1.02
Sulforaphane: translational research from laboratory bench to clinic. Nutr Rev (2013) 1.01
Effects of exercise and lifestyle intervention on cardiovascular function in CKD. Clin J Am Soc Nephrol (2013) 1.01
Astaxanthin in cardiovascular health and disease. Molecules (2012) 1.01
The impact of high-intensity interval training versus moderate-intensity continuous training on vascular function: a systematic review and meta-analysis. Sports Med (2015) 1.00
Influence of high-intensity interval training on adaptations in well-trained cyclists. J Strength Cond Res (2005) 0.99
Short-duration mechanical ventilation enhances diaphragmatic fatigue resistance but impairs force production. Chest (2003) 0.99
Pulse pressure amplification during exercise is significantly reduced with age and hypercholesterolemia. J Hypertens (2007) 0.96
Effects of atorvastatin on NGAL and cystatin C in chronic kidney disease: a post hoc analysis of the LORD trial. Nephrol Dial Transplant (2011) 0.96
Exercise training in chronic kidney disease patients. Sports Med (2012) 0.94
Exposure to automotive pollution increases plasma susceptibility to oxidation. Arch Environ Health (2003) 0.94
Ultra-endurance exercise and oxidative damage : implications for cardiovascular health. Sports Med (2006) 0.93
Effect of atorvastatin on kidney function in chronic kidney disease: a randomised double-blind placebo-controlled trial. Atherosclerosis (2010) 0.88
Effect of intradialytic versus home-based aerobic exercise training on physical function and vascular parameters in hemodialysis patients: a randomized pilot study. Am J Kidney Dis (2009) 0.87
Determinants of changes in blood glucose response to short-term exercise training in patients with Type 2 diabetes. Clin Sci (Lond) (2008) 0.87
The effects of immunosuppressants on vascular function, systemic oxidative stress and inflammation in rats. Transpl Int (2012) 0.86
Statins in acute kidney injury: friend or foe? BMJ (2013) 0.86
Physical activity levels in patients with chronic kidney disease entering the LORD trial. Med Sci Sports Exerc (2009) 0.86
Intradialytic versus home-based exercise training in hemodialysis patients: a randomised controlled trial. BMC Nephrol (2009) 0.86
Effects of atorvastatin on arterial stiffness in chronic kidney disease: a randomised controlled trial. J Atheroscler Thromb (2009) 0.86
Bcl-2 in endothelial cells is increased by vitamin E and alpha-lipoic acid supplementation but not exercise training. J Mol Cell Cardiol (2005) 0.86
Effect of tocopherol on atherosclerosis, vascular function, and inflammation in apolipoprotein E knockout mice with subtotal nephrectomy. Cardiovasc Ther (2014) 0.85
Alpha-tocopherol and alpha-lipoic acid enhance the erythrocyte antioxidant defence in cyclosporine A-treated rats. Basic Clin Pharmacol Toxicol (2006) 0.85
Astaxanthin vs placebo on arterial stiffness, oxidative stress and inflammation in renal transplant patients (Xanthin): a randomised controlled trial. BMC Nephrol (2008) 0.85
Vitamin E and alpha-lipoic acid supplementation increase bleeding tendency via an intrinsic coagulation pathway. Clin Appl Thromb Hemost (2006) 0.85
In vitro permeability and metabolic stability of bile pigments and the effects of hydrophilic and lipophilic modification of biliverdin. Bioorg Med Chem (2008) 0.85
Glutathione peroxidase, superoxide dismutase and catalase genotypes and activities and the progression of chronic kidney disease. Nephrol Dial Transplant (2011) 0.84
Dose response of caffeine on 2000-m rowing performance. Med Sci Sports Exerc (2010) 0.84
Changes in neutrophil surface receptor expression, degranulation, and respiratory burst activity after moderate- and high-intensity exercise. J Appl Physiol (1985) (2004) 0.84
Patients with type 2 diabetes have exaggerated brachial and central exercise blood pressure: relation to left ventricular relative wall thickness. Am J Hypertens (2008) 0.84
Bovine colostrum modulates cytokine production in human peripheral blood mononuclear cells stimulated with lipopolysaccharide and phytohemagglutinin. J Interferon Cytokine Res (2009) 0.84
Dietary intake of patients with chronic kidney disease entering the LORD trial: adjusting for underreporting. J Ren Nutr (2007) 0.83
Acute response of blood glucose to short-term exercise training in patients with type 2 diabetes. J Sci Med Sport (2010) 0.83
Simultaneous measurement of aldosterone and cortisol by high-performance liquid chromatography-tandem mass spectrometry: application to dehydration-rehydration studies. J Chromatogr B Analyt Technol Biomed Life Sci (2010) 0.83
Effect of pravastatin on kidney function and urinary protein excretion in autosomal dominant polycystic kidney disease. Scand J Urol Nephrol (2010) 0.82
Laparoscopic gastric banding surgery performed in obese dialysis patients prior to kidney transplantation. Am J Kidney Dis (2008) 0.82
Central and peripheral adjustments during high-intensity exercise following cold water immersion. Eur J Appl Physiol (2013) 0.82
Variability in oxidative stress biomarkers following a maximal exercise test. Biomarkers (2013) 0.82
Antioxidant requirements of endurance athletes: implications for health. Nutr Rev (2006) 0.82
Exercise and the endothelial cell. Int J Cardiol (2005) 0.81
SYNbiotics Easing Renal failure by improving Gut microbiologY (SYNERGY): a protocol of placebo-controlled randomised cross-over trial. BMC Nephrol (2014) 0.81
The Lipid lowering and Onset of Renal Disease (LORD) Trial: a randomized double blind placebo controlled trial assessing the effect of atorvastatin on the progression of kidney disease. BMC Nephrol (2008) 0.81
Exercise & Sports Science Australia (ESSA) position statement on exercise and chronic kidney disease. J Sci Med Sport (2013) 0.81
Nitric oxide does not significantly contribute to changes in pulse pressure amplification during light aerobic exercise. Hypertension (2008) 0.81
Effects of bovine colostrum supplementation on immune variables in highly trained cyclists. J Appl Physiol (1985) (2006) 0.81
No relationship between low-density lipoproteins and endothelial function in hemodialysis patients. Int J Cardiol (2005) 0.81
Effects of atorvastatin on biomarkers of inflammation in chronic kidney disease. Clin Nephrol (2014) 0.80
The effect of consecutive days of exercise on markers of oxidative stress. Appl Physiol Nutr Metab (2007) 0.80
Pre-existing inflammatory state compromises heat tolerance in rats exposed to heat stress. Am J Physiol Regul Integr Comp Physiol (2006) 0.80
Effect of atorvastatin on cognitive function in patients from the Lipid Lowering and Onset of Renal Disease (LORD) trial. Pharmacotherapy (2007) 0.80
Assessment of arterial stiffness, oxidative stress and inflammation in acute kidney injury. BMC Nephrol (2009) 0.79
Vascular function and mortality in haemodialysis patients: a pilot study. Arch Cardiovasc Dis (2011) 0.79
Time course and dose response of alpha tocopherol on oxidative stress in haemodialysis patients. BMC Nephrol (2009) 0.79
Optimising exercise training in peripheral arterial disease. Sports Med (2004) 0.79
Influence of carbohydrate on serum caffeine concentrations following caffeine ingestion. J Sci Med Sport (2012) 0.78
Pulmonary oedema and hyponatraemia after an ironman triathlon. BMJ Case Rep (2009) 0.78
Optimising high-intensity treadmill training using the running speed at maximal O(2) uptake and the time for which this can be maintained. Eur J Appl Physiol (2003) 0.78
Variability of oxidative stress biomarkers in hemodialysis patients. Biomarkers (2014) 0.78
Relationship between antioxidant enzyme genotype and activity and kidney function: a case-control study. Clin Nephrol (2012) 0.78
Glutathione depletion and acute exercise increase O-GlcNAc protein modification in rat skeletal muscle. Mol Cell Biochem (2014) 0.78
Performance benefits of rehydration with intravenous fluid and oral glycerol. Med Sci Sports Exerc (2012) 0.78
The role of exercise training in the management of chronic kidney disease. Curr Opin Nephrol Hypertens (2015) 0.78
Cardiorespiratory Fitness, Sedentary Time, and Cardiovascular Risk Factor Clustering. Med Sci Sports Exerc (2016) 0.77
Effects of antioxidant supplementation and exercise training on erythrocyte antioxidant enzymes. Int J Vitam Nutr Res (2006) 0.77
Nutritional compounds influence tissue factor expression and inflammation of chronic kidney disease patients in vitro. Nutrition (2011) 0.77
Physiological and performance effects of glycerol hyperhydration and rehydration. Nutr Rev (2009) 0.77
Effects of exercise training and RhoA/ROCK inhibition on plaque in ApoE-/- mice. Int J Cardiol (2012) 0.77
Effects of exercise and antioxidant supplementation on endothelial gene expression. Int J Cardiol (2011) 0.77
Endurance exercise, plasma oxidation and cardiovascular risk. Acta Cardiol (2004) 0.77
Fitness Is Independently Associated with Central Hemodynamics in Metabolic Syndrome. Med Sci Sports Exerc (2016) 0.77
Central hemodynamics in ultra-endurance athletes. J Sci Med Sport (2007) 0.77
12 min/week of high-intensity interval training reduces aortic reservoir pressure in individuals with metabolic syndrome: a randomized trial. J Hypertens (2016) 0.76
The effects of dietary fish oil on inflammation, fibrosis and oxidative stress associated with obstructive renal injury in rats. Mol Nutr Food Res (2010) 0.76
Use of intravenous rehydration in the National Football League. Clin J Sport Med (2011) 0.76
Contribution of autonomic dysfunction to abnormal exercise blood pressure in type 2 diabetes mellitus. J Sci Med Sport (2012) 0.76
Cyclosporine A induced changes to plasma and erythrocyte antioxidant defences. Redox Rep (2005) 0.76
Comparison of markers of oxidative stress, inflammation and arterial stiffness between incident hemodialysis and peritoneal dialysis patients--an observational study. BMC Nephrol (2009) 0.76
Cyclosporine A-induced changes to erythrocyte redox balance is time course-dependent. Basic Clin Pharmacol Toxicol (2005) 0.76